
    
      The duration of each participant's participation in the study is approximately 7 months (28
      day-vaccination period followed by 6 month safety follow-up period). For the subset of adults
      who receive a single booster dose of VRVg-2, the duration is approximately 18 months (1
      booster dose 12 months after the first injection, followed by a 6 month safety follow-up
      period).
    
  